 
DJ Sinclair Pharma Plc Trading Update - Strong Performance
TIDMSPH
SPH.L
Trading update for the year ended 30 June 2010
Restructuring drives strong performance across group
Sinclair Pharma plc ("Sinclair" or "the Company": SPH:L), the international
specialty pharma company, today issues its trading update for the year ended 30
June 2010 ahead of the close period preceding the announcement of its
preliminary results, planned for the middle of September.
* Restructuring continues to deliver significant benefits across the business
* Revenues for the year ended 30 June 2010 exceeded GBP27m
* 23% like-for-like growth from Italian business post business realignment
* Flammazine integration proceeding well with revenue contribution of GBP4.2m
for the year
Sinclair is pleased to report that full year revenues exceeded GBP27m, GBP26m
excluding licensing income, compared to GBP23m excluding licensing to June 2009.
Our Italian operation performed particularly strongly with like for like
revenue growth of 23%. We are also pleased to announce that Sinclair's
manufacturing facility at Cléry for the first time produced over 3 million
units in the second half, as the strategy to increase utilisation and improve
gross margins started to produce results.
The Company continues to negotiate a number of deals for Decapinol/delmopinol
and is also actively pursuing opportunities in emerging market territories for
multi country, multi product deals with further announcements expected in the
coming months.
As discussed in the recent interim management statement, the Company intends to
announce its new product pipeline and strategy in the near future. Progress has
been made in identifying targets in our core markets and therapy areas, and we
look forward to updating shareholders later this year.
The integration of Flammazine and Flammacerium continues smoothly. The Company
is currently investigating several possibilities for line and geographical
extensions as well the development of the Flammacerium franchise. Flammazine
and Flammacerium contributed revenue of GBP4.2m in the period since acquisition.
Chris Spooner, CEO of Sinclair, commented:
"Restructuring continues apace, and I am delighted with the dramatic
improvement in the company's culture and operational performance during the
second half, which is a credit to the hard-work and dedication of our employees
and new management team. Before I joined Sinclair, I had the view that the
company would prove an excellent platform from which to build a leading
specialist dermatology and oral care business. Recent discussions with
potential partners and our improving performance trends give me great
encouragement. I firmly believe that our strategy is beginning to deliver".
Ends
For further information please contact:
Sinclair Pharma plc Tel: +44 (0) 1483 410 600
Chris Spooner, CEO
Alan Olby, CFO
Singer Capital Markets Ltd Tel: +44 (0)20 3205 7500
Shaun Dobson
Claes Spång
Biddicks, Financial Public Relations Tel: +44 (0)20 7448 1000
Shane Dolan
Notes to Editors:
About Sinclair Pharma Plc www.sinclairpharma.com
Sinclair Pharma plc is an international specialty pharmaceutical company
providing solutions to treat wounds, dermatological and oral diseases through
advanced surface technology and innovative delivery systems. It has a growing
sales and marketing operation that is present in France, Italy, Germany and
Spain, and an extensive marketing partner network across selected developed &
emerging markets.
"Safe Harbor" Statement under the US Private Securities Litigation Reform Act
of 1995: Some or all of the statements in this document that relate to future
plans, expectations, events, performances and the like are forward-looking
statements, as defined in the US Private Securities Litigation Reform Act of
1995. Actual results of events could differ materially from those described in
the forward-looking statements due to a variety of factors.
(END) Dow Jones Newswires
16-07-10 0601GMT
|
